Pfizer Presents Positive Real-World Evidence for First-Line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer at ESMO Breast Cancer 2022

PRESS RELEASE Research Findings

22/06/2022

Pfizer Inc.

NEW YORK, NY, May 4, 2022 – Pfizer Inc. (NYSE:PFE) announced today the presentation of real-world evidence demonstrating an associated benefit for patients treated with IBRANCE® (palbociclib) in combination with an aromatase inhibitor (AI), as compared to AI alone, in the first-line setting, at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 Congress. This retrospective cohort study is a large comparative effectiveness study of 2,888 hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) patients evaluating IBRANCE in combination with AI compared to AI alone and demonstrated an associated improved overall survival (OS) in post-menopausal women and in men with HR+, HER2- mBC treated in routine clinical practice in the United States.

Related News

GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Government will purchase an additional 600,0...

17/01/2022

PRESS RELEASE Corporate Announcements

ADUHELM™ (Aducanumab) ยารักษาโรคอัลไซเมอร์ตัวแรกและตัวเดียว ที่ได้รับการอนุมัติเร่งด่วนจาก FDA

8 มิถุนายน 2021 – Biogen (Nasdaq: BIIB, CEO: Michel Vounatsos, ต่อจากนี้จะเรียกแทนว่า Biogen) และ Eisai Co., Ltd. (CEO: Haruo Naito, ต่อจากนี้จะเรียกแ...

14/06/2021

PRESS RELEASE FDA Approval

AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU

AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionise cancer care at the 2022 Amer...

18/01/2022

PRESS RELEASE Corporate Announcements

Terumo Aortic Announces PMDA Approval for RelayPro Endovascular Device in Japan

Terumo Aortic today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval of the RelayPro Thoracic Stent-...

15/12/2021

PRESS RELEASE Product Launch

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509,1710

15th,17th floor South Sathorn road Yannawa

Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com

 

Contact Us